You are building a wellness company. A supplement brand. A fitness app. A coaching practice. You have the vision. You have the guts. You do not have the map. And you are scared of working hard in the wrong direction and running out of money before you figure it out.
You hired a consultant. Or you are about to. They gave you a strategy deck. A market analysis. A brand framework. It felt like progress. Then they left. And you discovered the deck did not tell you which sentence on your website triggers an FDA warning letter. It did not tell you that selling into Canada requires a pre-market licence you have not applied for. It did not tell you that your testing program satisfies one country’s rules and fails the other’s.
Direct Answer: Off-the-shelf consulting fails wellness businesses for four structural reasons. First, it solves the wrong problem: it optimizes for growth before it secures legality. Second, it works in the wrong order: it builds brand and acquisition before it builds regulatory and financial infrastructure. Third, it operates on the wrong incentive: it bills for deliverables, not outcomes, so it has no reason to stay. Fourth, it leaves before the consequences appear: the warning letter, the border seizure, the cash shortfall from a nine-month licensing delay. Wellness businesses have industry-specific constraints that generic consulting often treats as downstream details. Those details can determine whether the business can launch, sell, expand, or remain solvent.
Here is what that looks like in practice, with the specific regulations, timelines, and financial decisions generic firms often never touch.
Table of Contents
Failure One: Solving the Wrong Problem
Failure Two: Working in the Wrong Order
Failure Three: The Wrong Incentive Structure
Failure Four: Leaving Before the Consequences
What Industry-Specific Consulting Does Instead
The Work Continues After the Strategy
Straight Answers
1. Failure One: Solving the Wrong Problem
Off-the-shelf consulting assumes your biggest problem is growth. That assumption is the first and most consequential error, because it misidentifies the binding constraint on the business. For a wellness company, the binding constraint is not demand generation. It is the tandem problem of legality and solvency. Growth is a third-order problem that becomes irrelevant if the first two are unresolved, and a strategy that treats it as the primary objective is optimizing for a variable that cannot yet be safely pursued.
The FDA’s enforcement record demonstrates this with precision. On January 22, 2026, the agency issued a warning letter to Diamond-Herpanacine of PA, Inc. The FDA reviewed the company’s website and Facebook page in September 2025. The conclusion: the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act because they are intended for use in the cure, mitigation, treatment, or prevention of disease.
The evidence was not a lab test. It was not a facility inspection. It was the company’s own marketing copy:
-
Website: “the National Eye Institute, a department of the NIH, announced that several of our powerful ingredients – are effective … in the fight against ocular degenerative disease”
-
Facebook: “LYSINE1 Attacks the herpes virus” and “SELENIUM Directly attacks viral particles”
-
Testimonial: “I’ve been aware that I have the beginnings of macular degeneration for more than a year… Diamond Eye Health has all I require and more”
The regulatory distinction at issue is not obscure, but it is decisive. A structure/function claim describes how a nutrient affects normal body function and is permitted with substantiation and a 30-day notification to the FDA. A disease claim states or implies a relationship between the product and a disease. That distinction determines whether the product is a supplement or a drug. A drug requires premarket approval the company did not have.
A generic consultant’s entire engagement was designed to produce demand. It never asked whether the demand-generating copy was legal. That is the structural failure: the engagement solved for the wrong problem, and the growth problem was never the binding constraint. The legality problem was.
2. Failure Two: Working in the Wrong Order
Generic consulting builds brand first, acquisition second, and compliance last. For wellness businesses, that sequence is inverted, and the inversion is not a matter of preference but of structural necessity. The correct order is legality, then solvency, then growth, because each stage depends on the conditions established by the one before it. A brand built on claims that trigger regulatory reclassification is not an asset; it is a liability. An acquisition engine that drives traffic to a product that cannot legally be sold is not growth; it is exposure.
The Canadian market illustrates the cost of the wrong order with unusual clarity. From March 10 to March 23, 2026, Health Canada conducted Operation Pangea XVIII. The agency inspected 1,481 packages entering the country. It blocked 880 packages, or 59 percent. It seized an additional 56 packages containing suspected counterfeit or unauthorized health products, valued at an estimated $1,353,829.
The regulatory logic is inverted from the United States, and that inversion has direct commercial consequences:
-
In the US, the FDA does not pre-approve your label. In Canada, Health Canada reviews your documentation before granting a Natural Product Number.
-
Unauthorized health products have not been assessed by Health Canada for safety, efficacy, and quality. If you are shipping to Canadian customers without an NPN or Drug Identification Number, you are selling an unauthorized product into a market that is actively intercepting shipments.
-
You cannot sell until the licence is granted. The launch date is set by Health Canada, not by your growth projections.
The timeline is not short, and it is not predictable in the way a financial model requires. Health Canada classifies NHP applications into three categories. Class I fully attests to a single Compendium monograph. Class II relies on monographs with parameters not fully covered. Class III involves novel claims or ingredients not covered by a monograph. In fiscal year 2024-25, Class III applications were 35 percent of submissions. Only 47 percent met the 210-day service standard. Actual licensing averaged approximately 260 days.
A generic consultant will tell you to expand to Canada. That advice is delivered before the licence application is even drafted. The order is wrong. An industry-specific consulting process builds the NPN timeline into the runway calculation before you commit to the launch, because the launch date is not a marketing decision. It is a regulatory outcome.
3. Failure Three: The Wrong Incentive Structure
Generic consultants bill for deliverables. Decks. Frameworks. Workshops. The invoice is tied to the artifact, not the outcome. This creates a structural misalignment that is not incidental to the business model but constitutive of it: the consultant is paid whether or not the business works. The deliverable is complete. The engagement is over. The warning letter arrives six months later, addressed to you.
This is not a character flaw in individual consultants. It is the business model, and the business model determines the behavior. A consulting engagement can be perfectly competent within its defined scope and still fail the business if the scope ends before the consequences of the advice become visible.
That temporal gap is particularly consequential in wellness, because the distance between a recommendation and its consequence can be long:
-
A claims decision can affect regulatory classification months later.
-
A licensing delay can affect revenue projections months after the market-entry decision.
-
A testing requirement can emerge after the financial model has already assumed production.
-
A labelling change can create additional costs after packaging has already been ordered.
The consultant has completed the assignment. The business has inherited the consequences. The problem is therefore not simply whether the consultant produced a good deliverable. The problem is whether the engagement was structured around the actual time horizon of the business decision.
When the work is built around the outcome rather than the document, the incentive changes. The person advising on the launch has a reason to care whether the launch can actually happen. The person building the financial model has a reason to care whether the assumptions survive the regulatory timeline. The distinction matters because wellness businesses do not stop experiencing consequences when the consulting engagement ends.
4. Failure Four: Leaving Before the Consequences
The final failure is temporal. Generic consultants exit before the consequences of their advice appear. The FDA warning letter takes months to arrive. The border seizure happens at the shipment, not the strategy session. The NPN delay shows up in the cash flow model nine months after the launch decision. None of these consequences are visible during the engagement. They are visible after.
A consultant who leaves at the end of the engagement never sees the consequence. A business owner does. That asymmetry changes the advice.
When you know you will still be involved when the cash runs short, you model the cash more conservatively. When you know you will be the one explaining the warning letter, you read the copy before it publishes. When you know the expansion decision has to survive a licensing process, you build that process into the financial model before calling the expansion a growth opportunity.
The incentive and the timeline are linked. Staying forces better advice. This is where the limitations of off-the-shelf consulting become particularly visible: a generic engagement can produce a technically complete strategy while leaving the business exposed to consequences that were never part of the scope.
5. What Industry-Specific Consulting Does Instead
When a client comes to us with a wellness launch plan, the work has to begin with the constraints that can determine whether the plan is viable. That is not a matter of adding compliance as a later workstream. It is a matter of treating the regulatory, testing, labelling, and financial constraints as inputs to the commercial decision rather than as downstream implementation details.
The practical work is specific, and it is financial:
-
We read every piece of marketing copy for disease claims, because a claim can change the regulatory classification and therefore the entire commercial pathway.
-
We map the NPN application class and build the review timeline into the 13-week cash flow, because a nine-month licensing delay is a cash-flow event before it is a market-entry event.
-
We audit the raw material testing program against both 21 CFR 111 and Health Canada’s Compendium requirements, because a lot that passes one framework may fail the other.
-
We build the label redesign cost into the budget year that precedes June 2028, because packaging is a working-capital decision, not a compliance afterthought.
On the testing front specifically: under 21 CFR 111.75, US manufacturers must conduct at least one appropriate test to verify the identity of any dietary ingredient. Health Canada’s Compendium specifies preferred analytical methods. USP <232> sets permitted daily exposure for oral products: arsenic 15 micrograms per day, cadmium 5 micrograms per day, lead 5 micrograms per day, mercury 30 micrograms per day. A lot that passes your US specification may fail Canada’s. Your testing program must satisfy two frameworks before you list a single SKU.
On labelling: Health Canada amended the Natural Health Products Regulations in 2022 to require a standardized Product Facts Table, priority allergen labelling, increased font size, and modernized contact information. Products have until June 22, 2028, to comply. Products authorized before June 21, 2025, have a three-year transition period. Products authorized on or after that date are exempt if labelled under the old rules.
None of this is optional. All of it is financial. A consulting process that understands the wellness industry has to account for these requirements before the commercial decision is made, not after the strategy has already been approved. The point is not to turn every consultant into a regulatory specialist. It is to understand which specialist questions can change the commercial answer:
-
If a claim changes the regulatory classification, that affects the marketing strategy.
-
If a licence takes nine months, that affects the revenue forecast.
-
If additional testing is required for a second market, that affects the cost of expansion.
-
If packaging has to be redesigned before a transition deadline, that affects working capital.
Those are not separate compliance issues sitting somewhere downstream from the business strategy. They are business decisions.
6. The Work Continues After the Strategy
Most consulting firms leave when the project ends. The problem is that the project ending does not mean the business problem has ended. The NPN still has to be granted. The label still has to be produced. The testing still has to be completed. The product still has to cross the border. The customer still has to buy it. And the cash still has to last until that happens.
This is why industry-specific consulting has to account for what happens after the strategy is delivered. A recommendation to enter Canada is also a licensing question. A recommendation to change positioning is also a claims question. A recommendation to launch in Q3 is also a cash-flow question. A recommendation to expand the product line is also a testing, inventory, and working-capital question.
The strategy cannot be separated cleanly from those realities. That does not mean every consultant needs to stay indefinitely. It means the scope of the work needs to match the nature of the problem. For wellness businesses, the real work often begins where generic consulting considers the engagement finished.
7. Straight Answers
Q: What is the single biggest reason off-the-shelf consulting fails wellness businesses?
A: It solves the wrong problem. It optimizes for growth before it secures legality and solvency. The FDA does not need to test your product. Your own marketing copy is the evidence that can classify it as an unapproved new drug.
Q: Why does generic consulting struggle with the wellness industry?
A: Wellness businesses operate under constraints that vary by product, claim, jurisdiction, and operating model. A supplement company, fitness business, coaching practice, and digital wellness platform can all sit under the wellness umbrella while facing very different regulatory, operational, and financial requirements.
Q: How long does an NPN application take in Canada?
A: Timeline varies by class. Class I fully attests to a single monograph. Class III requires supporting evidence for non-monographed parameters. In fiscal year 2024-25, only 47 percent of Class III applications met the 210-day service standard. Actual licensing averaged approximately 260 days.
Q: Can I use my US testing data for my Canadian NPN application?
A: Not automatically. Identity testing methods must align with Health Canada’s Compendium. Heavy metal limits are expressed differently. Potency documentation requires quantitative data. Budget for supplementary testing.
Q: What happens if I sell in Canada without an NPN?
A: You are selling an unauthorized health product. Health Canada blocked 59 percent of inspected packages during Operation Pangea XVIII. You risk seizure and market access denial.
Q: When do I need to comply with the new Canadian labelling requirements?
A: June 22, 2028. Products authorized before June 21, 2025, have a transition period. Products authorized on or after that date are exempt if labelled under the old rules. Build the label redesign cost into your 2026 or 2027 budget.
Q: How do I know whether my consultant understands the wellness industry?
A: Ask them to connect the commercial recommendation to the operational constraints behind it. Can they explain how a marketing claim affects regulatory classification? Can they account for an NPN timeline in the cash-flow model? Can they identify where US testing requirements differ from Canadian requirements? Can they explain what happens to the launch plan if licensing takes longer than expected? If those questions sit outside the scope of the engagement, the strategy may be treating the most consequential parts of the business as implementation details.